Robert W. Baird started coverage on shares of Castle Biosciences (NASDAQ:CSTL) in a report issued on Monday morning, BenzingaRatingsTable reports. The firm issued an outperform rating and a $27.00 target price on the stock.
Separately, Canaccord Genuity began coverage on shares of Castle Biosciences in a research note on Monday. They issued a buy rating and a $26.00 price target for the company. Five investment analysts have rated the stock with a buy rating, Castle Biosciences has a consensus rating of Buy and a consensus target price of $26.80.
Shares of CSTL stock opened at $19.93 on Monday. Castle Biosciences has a one year low of $17.11 and a one year high of $24.75.
Castle Biosciences Company Profile
Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.
Further Reading: Outstanding Shares
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.